Clinical trials: Tumor Angiogenesis
Angiogenic Breast Cancer
Safety and Efficacy of Ga68-IAC PET/CT for Diagnosis and Clinical Management in Metastatic Breast Cancer Patients
This is a phase I/IIa, open label, multicenter interventional study of Gallium-68 radiolabeled Integrin Adhesion Complex antagonist conjugate (Ga-68-IAC) Positron Emission Tomography (PET/CT) imaging, intended for diagnosis, and…
- Trial name
- Shiva (NCT04480619)
- Testing
- Ga-68-IAC
- Where
- 3 sites in India, South Africa
- Volunteers
- 25 people
- Sponsor
- Advanced Imaging Projects, LLC
Carcinoma, Renal Cell
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Phase II, multi-center, two-stage study utilising a randomised discontinuation design to evaluate the safety and efficacy of GW786034 (pazopanib) in adult subjects with locally recurrent or metastatic clear-cell Renal Cell…
- Trial name
- NCT00244764
- Testing
- GW786034
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 225 people
- Sponsor
- GlaxoSmithKline
Angina Pectoris
Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization
The purpose of this study is to determine whether a one-time intracoronary infusion of Ad5FGF-4 is effective in reducing the time to onset myocardial ischemia as measured by exercise treadmill testing and improving myocardial…
- Trial name
- AWARE (NCT00438867)
- Testing
- Ad5FGF-4
- Where
- 47 sites in United States
- Volunteers
- 300 people
- Sponsor
- Cardium Therapeutics
Advanced Solid Tumors
A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors
This is a first in human, open-label, sequential dose escalation and expansion study of AMG 780 in up to 62 subjects with advanced solid tumors.
- Trial name
- NCT01137552
- Testing
- AMG 780
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Amgen
Advanced Solid Tumors
A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors
The purpose of this study is to determine if CVX-241 (PF-05057459) is safe and tolerable when given as weekly infusions to adult patients with advanced solid tumors.
- Trial name
- NCT01004822
- Testing
- CVX-241
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Pfizer
Gestational Trophoblastic Neoplasia, Choriocarcinoma
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
The purpose of the study is to determine the overall response rate of single agent TRC105 and the combination of TRC105 and bevacizumab in patients with refractory GTN (including choriocarcinoma, placental site trophoblastic…
- Conditions
- Gestational Trophoblastic Neoplasia, Choriocarcinoma, Placental Site Trophoblastic Tumor, Epithelioid Trophoblastic Tumor
- Trial name
- NCT02664961
- Testing
- TRC105, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Advanced Cancer
PTC299 for Treatment of Advanced Cancer
Formation of new blood vessels (angiogenesis) is important for tumor growth in advanced cancer. It is known that tumors make a protein called vascular endothelial growth factor (VEGF).
- Trial name
- NCT00704821
- Testing
- PTC299, Docetaxel
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- PTC Therapeutics
Non-small Cell Lung Cancer
A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC)
The primary purpose of this study is to examine the safety of volociximab in combination with a standard treatment of carboplatin and paclitaxel in subjects previously untreated with chemotherapy for advanced stage (IIIB/IV)…
- Trial name
- NCT00654758
- Testing
- M200 (Volociximab), Carboplatin, Paclitaxel
- Volunteers
- 33 people
- Sponsor
- AbbVie
Renal Cell Carcinoma
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.
- Trial name
- NCT01354431
- Testing
- nivolumab
- Where
- 41 sites in United States, Canada and 2 more
- Volunteers
- 168 people
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteer
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRG-110 Following Intradermal Injection in Healthy Volunteers
MRG-110 is intended to promote the growth of new blood vessels by inhibiting a molecule called miR-92a. MRG-110 is being studied to determine if it can accelerate healing of wounds by improving blood flow into the wound area.
- Trial name
- NCT03603431
- Testing
- MRG-110
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- miRagen Therapeutics, Inc.
Angina Pectoris
Efficacy and Safety of Intracoronary Ad5FGF-4 in Patients With Stable Angina (AGENT-3)
The purpose of this study is to determine whether a single intracoronary infusion of Ad5FGF-4 is effective in improving exercise capacity measured by exercise treadmill testing, angina functional class, patient symptoms, quality…
- Trial name
- NCT00346437
- Volunteers
- 416 people
- Sponsor
- Cardium Therapeutics
Pancreatic Neoplasm
Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer
The main objective of the study was to evaluate the effectiveness of aflibercept treatment by comparison to placebo in increasing the overall survival (OS) in participants with metastatic pancreatic cancer, treated with…
- Trial name
- VANILLA (NCT00574275)
- Testing
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Gemcitabine
- Where
- 24 sites in United States, Argentina and 22 more
- Volunteers
- 546 people
- Sponsor
- Sanofi
Advanced Solid Tumors
To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of AMG 386 when used in combination with AMG 706, bevacizumab, sorafenib, or sunitinib and that at least one dose level from each combination…
- Trial name
- NCT00861419
- Testing
- Sorafenib, AMG 706, AMG 386
- Volunteers
- 88 people
- Sponsor
- Amgen
Stage IV Melanoma
A Study of Volociximab in Metastatic Melanoma
This is a Phase 2, multicenter, research study determining the effects of an investigational drug called volociximab in metastatic melanoma. The purpose of the study is to compare the clinical benefit and safety of volociximab.
- Trial name
- NCT00369395
- Testing
- volociximab
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- Abbott
Metastatic Renal Cell Carcinoma
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
This study will evaluate the safety and efficacy of Dovitinib versus sorafenib in patients with metastatic renal cell cancer.
- Trial name
- NCT01223027
- Testing
- Dovitinib, Sorafenib
- Where
- 199 sites in United States, Argentina and 25 more
- Volunteers
- 564 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma, Non-Hodgkin
Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma
The purpose of this study is to determine the selected dose of aflibercept when it is combined with R-CHOP treatment (Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisone +/- intrathecal Methotrexate) administered every…
- Trial name
- NCT00644124
- Testing
- aflibercept
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Sanofi
Breast Cancer Stage IV
A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients.
This study is a Phase I/II clinical evaluation of a new investigational agent, Lutetium-177-DOTAGA-IAC (HurlutinTM Lu-177) to treat patients with unresectable angiogenic breast cancer who have previously been treated with at…
- Trial name
- Heroine01 (NCT04469127)
- Testing
- Lutetium-177-DOTAGA-IAC
- Where
- 2 sites in India, South Africa
- Volunteers
- 100 people
- Sponsor
- Advanced Imaging Projects, LLC
Lung Cancer, Non-Small Cell
A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors
This is an open-label, two-arm, Phase I, dose escalation study to evaluate the safety and tolerability and to determine the optimal tolerated regimen(OTR) of pazopanib in combination with gemcitabine (Arm A) or pazopanib…
- Trial name
- NCT00678977
- Testing
- Pazopanib (GW786034), Gemcitabine, Cisplatin
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Metastatic Melanoma
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma
The purpose of this study is to determine the safety profile, pharmacokinetics, pharmacodynamics and maximum tolerated dose of RAF265 in patients with locally advanced and metastatic melanoma.
- Trial name
- CHIR-265-MEL01 (NCT00304525)
- Testing
- RAF265
- Where
- 11 sites in United States, Switzerland
- Volunteers
- 104 people
- Sponsor
- Novartis Pharmaceuticals
Peripheral Arterial Disease, Critical Limb Ischemia
ACPs in Severe PAD/CLI by Direct Intramuscular Injection
Study title: A Study of Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients with Critical Limb Ischemia ( ACPs-CLI ) Principle Investigator: Assoc.Prof. Pramook Mutirangura,M.D.
- Trial name
- NCT00523731
- Testing
- Angiogenic Cell Precursors (ACPs) or Vescell TM
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- TheraVitae Ltd.